Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dr. Sprengers et al. Reply.

Jan J Sprengers1, Dorinde M van Andel1, Hilgo Bruining2

  • 1UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands.

Journal of the American Academy of Child and Adolescent Psychiatry
|January 15, 2021
PubMed
Summary

This study investigated bumetanide for autism spectrum disorder (ASD), aiming to replicate findings and identify biomarkers for personalized treatment. Results may help tailor therapies for individuals with ASD by understanding treatment response variability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Analyses in Patient-Derived Neurons Establish Pathogenicity for <i>STXBP1</i> Splice Variant c.429+5G>A.

Human mutation·2026
Same author

Validation of the ED-15-NL, a Brief Session-by-Session Questionnaire to Measure Changes in Eating Disorder Cognitions and Behaviors.

The International journal of eating disorders·2026
Same author

Changing the Child: The Impact of Novel Treatments on the Identity of Children With Monogenic Neurodevelopmental Disorders.

Bioethics·2026
Same author

Qualitative EEG abnormalities in ASD reflect inhibition-dominated brain dynamics.

Scientific reports·2026
Same author

Climate-Related and Nature-Based Interventions for Mental Health: An Umbrella Review and Meta-Analysis.

JAMA psychiatry·2026
Same author

Dimensionality reduction of quantitative EEG and clinical profiles uncover associations with monogenic neurodevelopmental phenotypes in SNAREopathies.

Frontiers in neuroscience·2026

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition.
  • Altered chloride regulation and GABA polarity are implicated in some ASD cases.
  • Previous studies suggest bumetanide as a potential therapeutic agent for ASD.

Discussion:

  • The Bumetanide in Autism Medication and Biomarkers (BAMBI) trial aimed to replicate prior findings on bumetanide efficacy in ASD.
  • A key objective was to develop stratification biomarkers to predict treatment response.
  • Understanding variability in treatment response is crucial for personalized medicine in ASD.

Key Insights:

  • Reversed GABA polarity is a potential therapeutic target in a subset of ASD models.

Related Experiment Videos

  • The heterogeneity of ASD necessitates identifying biomarkers for treatment selection.
  • BAMBI trial sought to validate bumetanide's effects and explore predictive markers.

    • Outlook:

    • Further research is needed to elucidate the role of GABAergic signaling in ASD.
    • Biomarker discovery can lead to more precise and effective interventions for ASD.
    • Personalized treatment strategies are essential for managing the complexities of ASD.